Ipamorelin Biohacker and Longevity Stack Protocol: Doses, Cycles, Labs, and Evidence

What Is Ipamorelin and Why Do Biohackers Use It?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively binds the ghrelin receptor (GHSR-1a) to stimulate pulsatile growth hormone release from the anterior pituitary. Unlike older secretagogues such as GHRP-6 or GHRP-2, ipamorelin does not appreciably raise cortisol, aldosterone, or prolactin at clinical doses, which is the main reason longevity-focused practitioners prefer it.

Mechanism: Pulsatile GH Without the Cortisol Spike

GH secretagogues work through two independent axes. Ipamorelin acts on GHSR-1a to mimic ghrelin's GH-releasing effect. Sermorelin and CJC-1295 act on the GHRH receptor. Combining both axes (ipamorelin plus a GHRH analog) produces a synergistic pulse that more closely replicates youthful GH secretion patterns compared to either agent alone.

A 1999 pharmacological characterization published in the Journal of Endocrinology demonstrated that ipamorelin produced potent GH release in rats comparable to GHRP-6 while showing significantly less ACTH and cortisol stimulation, a finding that anchored its selectivity profile in the subsequent literature. [1]

Why the Longevity Community Adopted It

GH declines roughly 14% per decade after age 30, contributing to reduced lean mass, increased visceral adiposity, poorer sleep architecture, and slower tissue repair. Biohackers in the tradition popularized by physicians such as Peter Attia have focused on restoring youthful GH pulsatility as one pillar of a longevity protocol, alongside zone-2 cardio, resistance training, and metabolic monitoring. Ipamorelin's clean selectivity profile makes it easier to titrate without the confounding cortisol elevations seen with GHRP-2. [2]

Evidence Levels: What the Research Actually Shows

The honest starting point for any ipamorelin protocol is an accurate picture of the evidence. It is thin in healthy adults. That does not mean the compound lacks effect, but it does mean that every practitioner using it in a longevity context is operating partly from mechanistic inference and clinical observation rather than Phase III trial data.

Preclinical and Small Human Trial Data

A controlled crossover study (N=8 healthy men) showed that intravenous ipamorelin at 1 to 10 mcg/kg produced dose-dependent GH release peaking at 45 to 60 minutes post-injection and returning to baseline within 3 hours, confirming the pulsatile, physiologic pattern. [1] Animal studies in aged rats showed that chronic GHRP administration preserved lean body mass and bone mineral density compared to controls, providing the mechanistic rationale for longevity use. [3]

Evidence From the Broader GH Secretagogue Literature

The GHRH secretagogue literature provides the strongest adjacent human evidence. A randomized trial published in the Annals of Internal Medicine (N=65 healthy older adults) found that MK-677, an orally active GH secretagogue, increased IGF-1 by approximately 40% and improved fat-free mass and muscle strength versus placebo over 12 months, though fasting glucose rose modestly. [4] Ipamorelin operates through a partially overlapping receptor mechanism, so this trial is frequently cited by practitioners as analogous, but ipamorelin itself has not been studied in an equivalent trial in healthy aging adults.

Regulatory and Evidence-Level Transparency

The FDA has not approved ipamorelin for any indication in humans. The compound is classified as a research peptide and is compounded by 503A/503B pharmacies. A 2023 FDA advisory memo placed several peptides including ipamorelin on a list of substances under review for inclusion in the bulk compounding category, creating ongoing regulatory uncertainty. Practitioners prescribing it do so under an off-label / investigational framework. [5]

Evidence level summary for this protocol:

• GH release mechanism: well-characterized (in vitro and animal data, small human PK studies). Grade: B.
• Body composition benefit in healthy adults: extrapolated from MK-677 and sermorelin RCTs. Grade: C.
• Longevity or mortality benefit: no human trial data. Grade: Expert opinion / anecdotal.

The Standard Biohacker Protocol: Dose, Route, and Timing

The following protocol reflects current practice among longevity-oriented prescribers and is designed for healthy adults aged 35 to 65 with no contraindications (active malignancy, uncontrolled diabetes, severe sleep apnea, or pituitary pathology).

Dosing

| Peptide | Dose Per Injection | Frequency | Route | |---|---|---|---| | Ipamorelin (solo) | 200 to 300 mcg | Once nightly | Subcutaneous | | Ipamorelin + CJC-1295 (no-DAC) | 200 mcg + 100 to 200 mcg | Once nightly OR twice daily | Subcutaneous | | Ipamorelin + Sermorelin | 200 mcg + 200 to 300 mcg | Once nightly | Subcutaneous |

Starting dose: Begin at 100 mcg nightly for weeks 1 to 2 to assess tolerability, then advance to 200 to 300 mcg.

Maximum recommended dose in longevity practice: 300 mcg per injection. Higher doses do not produce proportionally greater GH release due to receptor saturation, and they increase the likelihood of water retention and transient hypoglycemia. [1]

Injection Timing

Bedtime injection is standard. GH is naturally secreted in pulses during slow-wave sleep, and exogenous secretagogue use timed to sleep onset amplifies rather than disrupts this pattern. If a second daily injection is used, the first should occur in the morning at least 30 minutes before eating, since food blunts the GH pulse.

Route and Reconstitution

Ipamorelin is supplied as lyophilized powder in 2 to 5 mg vials. Reconstitute with bacteriostatic water (1 to 2 mL per 5 mg vial). Inject subcutaneously into the lower abdomen, rotating sites. Use a 29 to 31 gauge, 0.5-inch insulin syringe. Store reconstituted peptide refrigerated and use within 30 days.

Cycle Structure and Off-Ramp Planning

Most longevity practitioners use a 12-weeks-on, 4-weeks-off cycle. The rationale is two-part: preventing receptor desensitization at the pituitary level, and allowing monitoring labs to reflect a clean baseline during the off phase.

Why 12 Weeks?

Preclinical data in rodents suggest pituitary GHSR-1a receptor downregulation begins after sustained agonist exposure beyond 8 to 12 weeks, though direct human data confirming this timeline are lacking. A 12-week cycle matches the duration of the MK-677 trial that showed measurable body composition change. [4] It also aligns with the IGF-1 monitoring schedule: draw at baseline, at week 6, and at week 12.

Extended or Continuous Use

Some longevity clinicians prescribe continuous low-dose ipamorelin (100 mcg nightly, no cycle break) on the premise that the GH deficit in aging adults provides a physiologic buffer against over-stimulation. This approach is not supported by trial data and requires closer IGF-1 monitoring every 6 to 8 weeks to ensure levels do not exceed the upper limit of the age-adjusted normal range, which the Endocrine Society defines as approximately 303 ng/mL for adults aged 30 to 50. [6]

Stack Combinations Used in Longevity Protocols

Ipamorelin is rarely used as a standalone agent in advanced biohacker stacks. Combining it with a GHRH-axis peptide creates dual stimulation, producing a larger and more sustained GH pulse than either alone.

Ipamorelin Plus CJC-1295 (No-DAC / Modified GRF 1-29)

This is the most widely used pairing. CJC-1295 no-DAC (also called Mod-GRF 1-29) has a half-life of approximately 30 minutes, which matches ipamorelin's action window for a synchronized pulse. The with-DAC version of CJC-1295 has a multi-day half-life and creates a sustained GH elevation, which some practitioners find less physiologic and harder to titrate.

A randomized study in 21 healthy adults found that CJC-1295 with-DAC produced dose-dependent IGF-1 increases of 28 to 92% over two weeks. [7] The no-DAC form is pharmacokinetically closer to natural GHRH and is preferred in the biohacker context for that reason.

Ipamorelin Plus BPC-157

BPC-157 (body protection compound 157) is added by some practitioners primarily for gut permeability, tendon repair, and systemic anti-inflammatory effects rather than GH modulation. There is no pharmacokinetic interaction between the two peptides. BPC-157 is administered at 250 to 500 mcg daily by subcutaneous injection or orally at 500 mcg. The evidence base for BPC-157 in humans is limited to case reports and preclinical data. [8]

Ipamorelin Plus Thymosin Beta-4 (TB-500)

TB-500 is included in higher-complexity stacks focused on tissue regeneration. It promotes actin polymerization and angiogenesis in preclinical models. The combination with ipamorelin is purely empirical at this point, with no controlled human trials. Practitioners using it typically cycle TB-500 at 2.0 to 2.5 mg twice weekly for 4 to 6 weeks, distinct from the ipamorelin cycle.

Monitoring Labs: What to Test and When

Running labs is not optional. It separates a clinically supervised longevity protocol from unsupervised self-experimentation.

Core Lab Panel

| Lab | Timing | Clinical Rationale | |---|---|---| | Serum IGF-1 | Baseline, week 6, week 12, 4-week off | Primary efficacy and safety marker | | Fasting glucose | Baseline, week 6, week 12 | GH raises insulin resistance; catch early | | HbA1c | Baseline, week 12 | Longer-term glucose signal | | Fasting insulin / HOMA-IR | Baseline, week 12 | Detects insulin resistance before glucose rises | | Cortisol (AM, fasting) | Baseline, week 12 | Confirm ipamorelin is not raising cortisol | | Prolactin | Baseline, week 6 | Confirm selective receptor profile | | Lipid panel | Baseline, week 12 | GH has favorable effects on LDL in some patients | | CBC with differential | Baseline | Rule out underlying pathology before starting |

IGF-1 Target Range

The goal in a longevity context is to bring IGF-1 to the mid-to-upper-normal range for chronological age, not to the ceiling. Exceeding 300 ng/mL in adults over 50 raises theoretical concern about cancer-promoting effects of chronically elevated IGF-1, a concern noted in observational data linking very high IGF-1 to colorectal and prostate cancer risk. [9] The Endocrine Society's 2011 GH deficiency guideline states: "The goal of GH replacement is to achieve and maintain serum IGF-1 concentrations in the normal range for age and sex." [6]

Glucose Monitoring

The MK-677 12-month RCT noted a statistically significant increase in fasting glucose (P<0.05) at higher doses. [4] Ipamorelin likely carries the same liability at supraphysiologic doses. Any patient with a fasting glucose above 100 mg/dL or an HbA1c above 5.6% at baseline warrants a more conservative approach: start at 100 mcg nightly and re-check glucose at 4 weeks.

Expected Timeline of Outcomes

Outcomes from growth-hormone secretagogue use in healthy adults generally follow a predictable sequence, though individual variation is substantial.

Weeks 1 to 2: Sleep and Recovery

Most users report improved sleep depth and more vivid dreaming within the first 1 to 2 weeks. This correlates with ipamorelin's amplification of the physiologic GH pulse during slow-wave sleep. Tissue recovery after exercise may feel subjectively faster.

Weeks 3 to 6: Skin, Hair, and Fluid Shifts

Some practitioners observe transient water retention in weeks 3 to 5, particularly in the hands and feet. This typically resolves as the body equilibrates. Skin texture and hair quality changes, if present, usually begin around week 4 to 6 and are attributed to increasing collagen synthesis downstream of rising IGF-1.

Weeks 6 to 12: Body Composition

Measurable changes in lean mass and body fat require at least 8 to 12 weeks of consistent use alongside resistance training and adequate protein intake. The MK-677 trial documented significant increases in fat-free mass at 12 months. [4] Expect modest changes in the 12-week window: practitioners typically report 1 to 2 kg lean mass gain and modest reductions in visceral fat as assessed by DEXA, though controlled data for ipamorelin specifically are absent.

Month 3 and Beyond

IGF-1 elevations plateau by weeks 6 to 8 on a stable dose. Body composition benefits compound over multiple cycles when the protocol is paired with 150+ minutes per week of moderate-intensity aerobic exercise and 1.6 to 2.2 g/kg/day dietary protein, consistent with the position statement from the American College of Sports Medicine on protein for muscle anabolism. [10]

Side Effects and Contraindications

Common Side Effects

• Water retention: Most common at doses above 300 mcg. Transient; resolves with dose reduction.
• Transient hypoglycemia: Particularly if injected in the fed state at high dose. Inject fasted or at bedtime.
• Injection site irritation: Rotate sites; use proper aseptic technique.
• Tingling or numbness: Reported in some users at higher doses, consistent with mild GH-related paresthesia seen in acromegaly literature.

Contraindications

Active or suspected malignancy is an absolute contraindication. Elevated IGF-1 signals promote cellular proliferation. Ipamorelin should not be used by anyone with a personal history of cancer, a first-degree family history of hormone-sensitive cancer, untreated sleep apnea, active pituitary pathology, uncontrolled type 2 diabetes, or pregnancy. [6]

Drug Interactions

Glucocorticoids blunt GH release and reduce ipamorelin efficacy. Thyroid hormone deficiency also reduces GH secretagogue response; confirm TSH is within normal range before starting. Insulin co-administration at the time of injection will blunt the GH pulse.

Sourcing and Legal Considerations

Ipamorelin is not an FDA-approved drug. It is available from 503A compounding pharmacies with a valid prescription. It cannot be legally marketed as a dietary supplement or sold over the counter. The quality and sterility of compounded peptides vary substantially between pharmacies. Always source from an FDA-registered 503A or 503B compounding pharmacy that provides a certificate of analysis (CoA) confirming identity, purity (greater than 99% by HPLC), and sterility.

The FDA's 2023 draft guidance on bulk drug substances placed ipamorelin under category review, meaning its availability through compounding channels may change. [5] Patients and prescribers should monitor FDA updates quarterly.